Physician profile
Tarah E Wilson
NPI 1548735228
$4,967.10
in general payments reported to CMS, 2019-2025
24 companies · $781 in 2025
The $781 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,046 · 2022: $318 · 2023: $963 · 2024: $1,858 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,602.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $885.90 | 2021-2024 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $749.51 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $538.55 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $519.28 | 2022-2025 | Farxiga, Brilinta, Lokelma |
| Novo Nordisk INC | $291.16 | 2024-2025 | Wegovy |
| Pfizer INC. | $290.43 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $201.47 | 2022-2025 | Verquvo |
| Si-Bone, INC. | $181.44 | 2021 | |
| Alnylam Pharmaceuticals INC. | $179.51 | 2024-2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.82 | 2023-2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $160.07 | 2023-2024 | Inpefa |
| Heartflow, INC. | $153.67 | 2025 | |
| Grt US Holding, INC. | $144.62 | 2021-2022 | |
| Scpharmaceuticals INC. | $91.83 | 2024 | |
| Allergan, INC. | $91.55 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $71.80 | 2022-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $60.53 | 2024 | Arcalyst |
| Amgen INC. | $55.56 | 2025 | Repatha, Repatha |
| Boston Scientific Corporation | $39.61 | 2023 | Watchman Access System |
| Impulse Dynamics (USA) INC. | $31.64 | 2025 | Optimizer |
| Sanofi-Aventis U.S. LLC | $20.45 | 2023 | |
| Lundbeck LLC | $18.57 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $12.16 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarah Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.